Asciminib is a novel inhibitor of <i>ABL1</i> and <i>ABL2</i> gene fusions in ALL but requires the ABL SH3 domain for efficacy-Reference-Cited by-同舟云学术

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Published:2024-08-29 Issue:9 Volume:144 Page:1022-1026
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Eadie Laura N.¹²^ORCID,Lagonik Elias¹³^ORCID,Page Elyse C.¹²^ORCID,Schutz Caitlin E.¹,Heatley Susan L.¹²^ORCID,McClure Barbara J.¹²^ORCID,Forgione Michelle O.¹²,Yeung David T.¹²⁴⁵^ORCID,Hughes Timothy P.¹²⁴⁵,White Deborah L.¹²⁴^ORCID

Affiliation:

1. 1Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

2. 2Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia

3. 3Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, Australia

4. 4Australasian Leukaemia and Lymphoma Group, Melbourne, Australia

5. 5Haematology Department, Royal Adelaide Hospital, Adelaide, Australia

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/144/9/1022/2239990/blood_bld-2024-024776-main.pdf

Reference18 articles.

1. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain;van Outersterp;Blood,2024

2. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study;Den Boer;Lancet Oncol,2009

3. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia;Mullighan;N Engl J Med,2009

4. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure;Hughes;N Engl J Med,2019

5. Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance;Hantschel;Haematologica,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib;Leukemia;2024-07-31